Zobrazeno 1 - 10
of 36
pro vyhledávání: '"FRANCESCA BUONTEMPO"'
Autor:
Annalisa Lonetti, Alessandra Cappellini, Alice Bertaina, Franco Locatelli, Andrea Pession, Francesca Buontempo, Camilla Evangelisti, Cecilia Evangelisti, Ester Orsini, Laura Zambonin, Luca Maria Neri, Alberto Maria Martelli, Francesca Chiarini
Publikováno v:
Journal of Hematology & Oncology, Vol 9, Iss 1, Pp 1-16 (2016)
Abstract Background Although in recent years, the introduction of novel chemotherapy protocols has improved the outcome of T cell acute lymphoblastic leukemia (T-ALL) patients, refractory and/or relapsing disease remains a foremost concern. In this c
Externí odkaz:
https://doaj.org/article/576f817b0ef64c36929d4cf10cc37244
Autor:
Sara Salucci, Sabrina Burattini, Francesca Buontempo, Ester Orsini, Lucia Furiassi, Michele Mari, Simone Lucarini, Alberto M. Martelli, Elisabetta Falcieri
Publikováno v:
European Journal of Histochemistry, Vol 62, Iss 2 (2018)
Marine organisms such as corals, sponges and tunicates produce active molecules which could represent a valid starting point for new drug development processes. Among the various structural classes, the attention has been focused on 2,2-bis(6-bromo-3
Externí odkaz:
https://doaj.org/article/da728837544a47319649faf11cf2f1b2
Autor:
Francesca Buontempo, Ester Orsini, Isabella Zironi, Lorenzo Isolan, Alessandra Cappellini, Stefania Rapino, Agostino Tartari, Domiziano Mostacci, Giorgio Cucchi, Alberto Maria Martelli, Marco Sumini, Gastone Castellani
Publikováno v:
PLoS ONE, Vol 13, Iss 6, p e0199312 (2018)
Radiation therapy is a useful and standard tumor treatment strategy. Despite recent advances in delivery of ionizing radiation, survival rates for some cancer patients are still low because of recurrence and radioresistance. This is why many novel ap
Externí odkaz:
https://doaj.org/article/203390efba3945018fd904a784dd604b
Autor:
Sara Salucci, Sabrina Burattini, Francesca Buontempo, Alberto Maria Martelli, Elisabetta Falcieri, Michela Battistelli
Publikováno v:
European Journal of Histochemistry, Vol 61, Iss 3 (2017)
Skin cells can respond to UVB-induced damage either by tolerating it, or restoring it through antioxidant activation and DNA repair mechanisms or, ultimately, undergoing programmed cell death, when damage is massive. Nutritional factors, in particula
Externí odkaz:
https://doaj.org/article/93bde68f5e384d35b22ede221b29bceb
Autor:
Lorenzo Isolan, Davide Laghi, Isabella Zironi, Marta Cremonesi, Cristina Garibaldi, Francesca Buontempo, Marco Sumini
Publikováno v:
Radiation Physics and Chemistry. 200:110296
Dosimetric analysis and experimental setup design for in-vivo irradiation with a Plasma Focus device
Autor:
D.A. Bradley, Lorenzo Isolan, F. Mariotti, S.M. Jafari, Marco Sumini, Francesca Buontempo, Francesco Teodori
Publikováno v:
Radiation Physics and Chemistry. 155:17-21
Looking at possible clinical applications of the Plasma Focus (PF) technology as medium-low energy extremely fast radiation source, aiming at the treatment of skin cancer pathologies, in vivo experiments on mice are a due step. To properly design the
Publikováno v:
Clinical Science. 132:543-568
Mechanistic target of rapamycin (mTOR) is the kinase subunit of two structurally and functionally distinct large multiprotein complexes, referred to as mTOR complex 1 (mTORC1) and mTORC2. mTORC1 and mTORC2 play key physiological roles as they control
Autor:
Isabella Zironi, Gastone Castellani, Francesca Buontempo, Marco Sumini, Domiziano Mostacci, G. Cucchi, Lorenzo Isolan, Agostino Tartari, A. Mazza
Publikováno v:
Radiation Physics and Chemistry. 140:452-457
none 9 no In a Plasma Focus device the plasma collapses into the pinch where it reaches thermonuclear conditions for a few tens of nanoseconds, becoming a multi-radiation source. The nature of the radiation generated depends on the gas filling the ch
Autor:
Francesca Chiarini, Cecilia Evangelisti, Camilla Evangelisti, Francesca Buontempo, James A. McCubrey, Daniela Bressanin, Ester Orsini, Alberto M. Martelli, Annalisa Lonetti, Alessandra Cappellini
Publikováno v:
International Journal of Oncology. 45:909-918
T-cell acute lymphoblastic leukemia (T-ALL) is a heterogeneous neoplastic disorder of immature hematopoietic precursors committed to the T-cell lineage. T-ALL comprises about 15% of pediatric and 25% of adult ALL cases. Even if the prognosis of T-ALL
Autor:
Francesca Buontempo, Camilla Evangelisti, Andrea Pession, Luca M. Neri, Francesca Chiarini, Annalisa Lonetti, Alessandra Cappellini, Laura Zambonin, Alice Bertaina, Alberto M. Martelli, Cecilia Evangelisti, Ester Orsini, Franco Locatelli
Publikováno v:
Journal of Hematology & Oncology, Vol 9, Iss 1, Pp 1-16 (2016)
Journal of Hematology & Oncology
Europe PubMed Central
Journal of Hematology & Oncology
Europe PubMed Central
Background Although in recent years, the introduction of novel chemotherapy protocols has improved the outcome of T cell acute lymphoblastic leukemia (T-ALL) patients, refractory and/or relapsing disease remains a foremost concern. In this context, a